Education
About Us
Working with TipRanks
Follow Us
FHLC - ETF AI Analysis
Top Page
Fidelity MSCI Health Care Index ETF (FHLC)
Rating:72Outperform
Price Target:―
Positive Factors
Strong Top Holdings
Several key holdings, including Johnson & Johnson, AbbVie, and Gilead Sciences, have delivered strong year-to-date performance, supporting the ETF’s overall returns.
Low Expense Ratio
The ETF has a very low expense ratio compared to industry averages, allowing investors to keep more of their gains.
Focused Sector Exposure
The ETF’s concentration in the health care sector provides targeted exposure to a historically resilient and essential industry.
Negative Factors
Over-Concentration in Health Care
Nearly all of the ETF’s assets are allocated to the health care sector, which limits diversification and increases sector-specific risk.
Weak Performance from Some Holdings
Top holdings like UnitedHealth and Merck have underperformed year-to-date, which could drag on the fund’s overall performance.
Limited Geographic Diversification
The ETF is heavily focused on U.S. companies, offering little exposure to international markets and global growth opportunities.
FHLC vs. SPDR S&P 500 ETF (SPY)
AUM2.84B
RegionNorth America
Expense Ratio0.08%
Beta0.52
IssuerFidelity
Inception DateOct 21, 2013
Dividend Yield1.37%
Asset ClassEquity
Index TrackedMSCI US IMI 25/50 Health Care
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. Volume138,744
30 Day Avg. Volume156,464
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
84.52Price Target Upside― Downside
Rating ConsensusModerate Buy
Number of Analyst Covering326
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
FHLC Summary
The Fidelity MSCI Health Care Index ETF (FHLC) is an investment fund that focuses on the health care sector, tracking the MSCI USA IMI Health Care Index. It includes companies from industries like pharmaceuticals, biotechnology, and medical equipment. Some well-known companies in this ETF are Eli Lilly & Co and Johnson & Johnson. Investors might consider FHLC for its potential growth, as health care is a vital and innovative industry driven by global demand and advancements in medicine. However, it’s important to know that the ETF’s performance is closely tied to the health care sector, so if this industry faces challenges, the fund’s value could drop.
How much will it cost me?The Fidelity MSCI Health Care Index ETF (FHLC) has an expense ratio of 0.084%, meaning you’ll pay $0.84 per year for every $1,000 invested. This is lower than average because it is passively managed, tracking an index rather than relying on active management strategies.
What would affect this ETF?The FHLC ETF, focused on the U.S. health care sector, could benefit from ongoing innovation in biotechnology and pharmaceuticals, as well as increasing demand for health care services driven by aging populations and advancements in medical technology. However, it may face challenges from regulatory changes, drug pricing pressures, or economic downturns that could impact health care spending. Its reliance on top holdings like Eli Lilly and Johnson & Johnson means company-specific events could also significantly influence performance.
FHLC Top 10 Holdings
The Fidelity MSCI Health Care Index ETF (FHLC) is heavily concentrated in the health care sector, with Eli Lilly leading the charge thanks to its strong financial performance and robust growth outlook. Johnson & Johnson also adds steady momentum with its strategic initiatives, while Merck's pipeline advancements bolster the fund's positioning. However, UnitedHealth is lagging, weighed down by challenges in its Medicare and Medicaid segments, and Abbott Laboratories is facing bearish momentum despite its strategic acquisitions. This U.S.-focused fund leans heavily on pharmaceuticals and biotechnology, making it a bet on innovation and demographic-driven health care demand.
Name | Company Name | Weight % | Market Value | Market Cap | Yearly Gain | Overall Rating |
|---|---|---|---|---|---|---|
| Eli Lilly & Co | 12.72% | $361.35M | $984.63B | 37.60% | 72 Outperform | |
| Johnson & Johnson | 7.47% | $212.21M | $492.24B | 40.05% | 78 Outperform | |
| AbbVie | 5.90% | $167.75M | $389.14B | 24.73% | 66 Neutral | |
| UnitedHealth | 4.70% | $133.59M | $309.81B | -32.14% | 72 Outperform | |
| Merck & Company | 4.07% | $115.74M | $266.67B | 7.77% | 80 Outperform | |
| Thermo Fisher | 3.50% | $99.54M | $229.63B | 13.76% | 72 Outperform | |
| Abbott Laboratories | 3.34% | $94.91M | $219.88B | 12.68% | 73 Outperform | |
| Intuitive Surgical | 3.08% | $87.56M | $200.78B | 11.46% | 78 Outperform | |
| Amgen | 2.62% | $74.47M | $172.70B | 25.99% | 77 Outperform | |
| Danaher | 2.30% | $65.41M | $166.25B | -1.05% | 75 Outperform |
FHLC Technical Analysis
Positive
―
Price Trends
72.97
Positive
69.70
Positive
66.50
Positive
Market Momentum
0.57
Positive
65.14
Neutral
71.78
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For FHLC, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 74.20, equal to the 50-day MA of 72.97, and equal to the 200-day MA of 66.50, indicating a bullish trend. The MACD of 0.57 indicates Positive momentum. The RSI at 65.14 is Neutral, neither overbought nor oversold. The STOCH value of 71.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FHLC.
FHLC Peer Comparison
Comparison Results
Performance Comparison
FHLC
Fidelity MSCI Health Care Index ETF
75.92
10.05
15.26%
VHT
Vanguard Health Care ETF
―
―
―
IBB
iShares Biotechnology ETF
―
―
―
XBI
SPDR S&P BIOTECH ETF
―
―
―
IHI
iShares U.S. Medical Devices ETF
―
―
―
IYH
iShares U.S. Healthcare ETF
―
―
―
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents